Skip to main content
GB

GENSPEED Biotech

The startup develops point-of-care testing technology that enables the rapid identification of specific bacteria and viruses, as well as the quantification of biomarkers in biological samples. This technology allows dentists to perform immediate diagnoses and initiate treatment for infections caused by common nosocomial pathogens and their resistances.

Krimml, ÖsterreichFounded 201615700+ followers
Updated 3 months ago

Funding

$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Traditional laboratory methods for pathogen identification and biomarker quantification can be time-consuming and require specialized equipment, delaying diagnosis and treatment decisions. Point-of-care testing options often lack the multiplexing capabilities and sensitivity of lab-based assays.

Solution

Genspeed Biotech provides a compact, automated point-of-care testing (POCT) platform that enables rapid, multiplexed analysis of biological samples. The GENSPEED xPOC system combines microfluidics, miniaturized opto-electronics, and automated processing to quantify up to 8 different analytes from a single drop of blood in 15-20 minutes. The platform is adaptable for both nucleic acid detection and protein analyses, delivering results comparable to traditional laboratory methods directly at the point of care.

Target Audience

The primary target audience includes test manufacturers seeking OEM solutions for rapid testing, as well as healthcare providers, including dentists, seeking point-of-care diagnostic tools.

Features

  • xPOC Immuno Multiplex technology allows quantification of up to 8 biomarkers simultaneously from 20-50 µl of capillary blood.
  • Automated rapid testing provides results in 15-20 minutes.
  • Multiplex micro-ELISA reduces test time compared to standard laboratory ELISA.
  • Adaptable platform for specific customer requirements.
  • Performance comparable with expensive laboratory methods.
  • IVD-CE certified hardware and software.
  • Currently available tests include Vitamin D, COVID-19 IgG, FSME/TBE IgG, and PerioPOC Pro for periodontitis pathogens.
This profile is AI-generated and may contain inaccuracies.